Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus

Vlachoyiannopoulos, PG; Mavragani, CP; Bourazopoulou, E; Balitsari, AV; Routsias, JG

dc.contributor.author	Vlachoyiannopoulos, PG	en
dc.contributor.author	Mavragani, CP	en
dc.contributor.author	Bourazopoulou, E	en
dc.contributor.author	Balitsari, AV	en
dc.contributor.author	Routsias, JG	en
dc.date.accessioned	2014-03-01T01:53:52Z
dc.date.available	2014-03-01T01:53:52Z
dc.date.issued	2004	en
dc.identifier.issn	0340-6245	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27133
dc.subject	CD40 peptides	en
dc.subject	antibodies	en
dc.subject	anti phospholipid syndrome	en
dc.subject	beta 2 glycoprotein I	en
dc.subject	systemic lupus erythematosus	en
dc.subject.classification	Hematology	en
dc.subject.classification	Peripheral Vascular Disease	en
dc.subject.other	GLYCOPROTEIN-I ANTIBODIES	en
dc.subject.other	TISSUE FACTOR EXPRESSION	en
dc.subject.other	ENDOTHELIAL-CELLS	en
dc.subject.other	B-CELLS	en
dc.subject.other	ANTICARDIOLIPIN ANTIBODIES	en
dc.subject.other	PLATELET ACTIVATION	en
dc.subject.other	KAPPA-B	en
dc.subject.other	CD40	en
dc.subject.other	INDUCTION	en
dc.subject.other	CLASSIFICATION	en
dc.title	Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2004	en
heal.abstract	Anti-beta2glycoprotein I (anti-beta2GPI) antibodies constitute the main autoantibody specificity in the sera of patients with antiphospholipid syndrome (APS). There is evidence that anti-beta2GPI antibodies induce the precoagulant activity of the endothelium by cross-linking the beta2 glycoprotein I (beta2GPI) on the cell surface. Since beta2GPI lacks intracellular domains, homology with other molecules such as CD40 that could initiate signaling, was extensively searched. A 86% homology between the amino acid position 239-245 of the CD40 and 7-13 of the beta2glycoprotein was found. The CD40 peptide corresponding to amino acids 239-245 of the CD40 molecule was synthesized and coupled to a multiple antigenic peptide carrier. Antibodies to CD40 peptide were found in 61.5% APS patients (n=39), in 72.7% of systemic lupus erythematosus (SLE) positive for anti-beta2GPI antibodies (n=11) and 31.6% of SLE negative for anti-beta2GPI antibodies (n=19), but not in rheumatoid arthritis patients (n=28) or controls (n=36). Antibodies to CD40 peptide were associated with arterial thrombosis and/or brain microinfarcts. Affinity purified anti-CD40 peptide antibodies as well as affinity purified anti-beta2GPI antibodies recognized both, the beta2GPI and the CD40 peptide. The specificity of this recognition was confirmed with homologous and heterologous inhibition experiments. Confocal microscopy experiments demonstrated this cross-recognition of CD40 and beta2GPI molecules, by the purified anti-CD40 peptide antibodies, at the protein level. Thus, antibodies reacting with the beta2GPI can react and potentially activate different cells which express CD40 molecules at their surface.	en
heal.publisher	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	en
heal.journalName	THROMBOSIS AND HAEMOSTASIS	en
dc.identifier.isi	ISI:000225793000022	en
dc.identifier.volume	92	en
dc.identifier.issue	6	en
dc.identifier.spage	1303	en
dc.identifier.epage	1311	en